Alpelisib (Standard)

(Synonyms: BYL-719 (Standard))
Revisión del cliente

Based on 1 Customer Validation

Alpelisib (BYL-719) (Standard) is the analytical standard of Alpelisib (HY-15244). This product is intended for research and analytical applications. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.86%
  • No. CAS: 1217486-61-7
  • Fòrmula: C19H22F3N5O2S
  • Peso molecular:441.47
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Product Information
  • Chemical Information
  • Pureza y Documentación
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00